Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease
Christopher J. Tyler(New York Medical College), Jesús Rivera–Nieves(University of Virginia), Brigid S. Boland, Parambir S. Dulai(Northwestern Medicine), William J. Sandborn(University of San Diego), Joanne Lannigan(National Institutes of Health), Thangaraj Karuppuchamy(University of California San Diego), Brian J. Capaldo(University of Virginia), Derek Patel(VA San Diego Healthcare System), Samuel B. Ho, Erik Ehinger(La Jolla Institute for Immunology), Tamara Pérez-Jeldres(Pontificia Universidad Católica de Chile), Joshua Boyer(University of California San Diego), Peter B. Ernst(University of Virginia), Lars Eckmann(University of San Diego)
Cited by 8
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k